Compare · CGIX vs UNH
CGIX vs UNH
Side-by-side comparison of Cancer Genetics, Inc. (CGIX) and UnitedHealth Group Incorporated (UNH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CGIX and UNH operate in Medical Specialities (Health Care), so they compete in similar markets.
- UNH carries a market cap of $438.96B.
- UNH has hit the wire 19 times in the past 4 weeks while CGIX has been quiet.
- UNH has more recent analyst coverage (25 ratings vs 0 for CGIX).
- Company
- Cancer Genetics, Inc.
- UnitedHealth Group Incorporated
- Price
- -
- $354.88+0.10%
- Market cap
- -
- $438.96B
- 1M return
- -
- +31.20%
- 1Y return
- -
- -15.55%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NASDAQ
- NYSE
- IPO
- n/a
- News (4w)
- 0
- 19
- Recent ratings
- 0
- 25
UnitedHealth Group Incorporated
UnitedHealth Group Incorporated operates as a diversified health care company in the United States. It operates through four segments: UnitedHealthcare, OptumHealth, OptumInsight, and OptumRx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health and well-being services to individuals age 50 and older, addressing their needs for preventive and acute health care services, as well as services dealing with chronic disease and other specialized issues for older individuals; Medicaid plans, children's health insurance program, and health care programs; medical and dental benefits; and hospital and clinical services. The OptumHealth segment provides access to networks of care provider specialists, health management services, care delivery, consumer engagement, and financial services. This segment serves individuals directly through care delivery systems, employers, payers, and government entities. The OptumInsight segment offers software and information products, advisory consulting arrangements, and managed services outsourcing contracts to hospital systems, physicians, health plans, governments, life sciences companies, and other organizations. The OptumRx segment provides pharmacy care services and programs, including retail network contracting, home delivery, specialty and compounding pharmacy, and purchasing and clinical, as well as develops programs in areas, such as step therapy, formulary management, drug adherence, and disease/drug therapy management. UnitedHealth Group Incorporated has partnership with the University of California, San Francisco to expand the mental health workforce in California. UnitedHealth Group Incorporated was incorporated in 1977 and is based in Minnetonka, Minnesota.
Latest CGIX
- SEC Form 4: John R Fletcher was granted 8,676 units of Common Stock
- SEC Form 4 filed by Marcus Boehm
- SEC Form 4 filed by Joanna Horobin
- SEC Form 4 filed by Howard Mcleod
- SEC Form 4 filed by Yung-Ping Yeh
- SEC Form 4 filed by R. Paul Hansen
- SEC Form 4 filed by E. Geoffrey Harris
- SEC Form 4 filed by Ralf Brandt
- SEC Form 4 filed by D.C. Andrew Lafrence
- SEC Form 4 filed by A John Roberts
Latest UNH
- UnitedHealthcare Champions Industry Effort to Standardize Prior Authorization Requirements
- UnitedHealth upgraded by Argus with a new price target
- SEC Form DEFA14A filed by UnitedHealth Group Incorporated
- SEC Form DEF 14A filed by UnitedHealth Group Incorporated
- UnitedHealth Group Incorporated filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- UnitedHealth Group Reports First Quarter 2026 Results
- UnitedHealthcare Eliminates Most Medical Prior Authorizations, Accelerates Payments for Key Rural Care Hospitals and Providers Nationwide
- Seabury Resources for Aging® Launches Groundbreaking Fund with Support from UnitedHealthcare to Keep Vulnerable Seniors Housed as Demand for Aging-in-Place Aid Surges
- UnitedHealthcare and Missouri Bootheel Regional Consortium Announce Collaboration to Strengthen Maternal Health and Patient-Provider Relationships
- UnitedHealth upgraded by HSBC Securities with a new price target